首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   122057篇
  免费   12657篇
  国内免费   4906篇
耳鼻咽喉   1431篇
儿科学   2372篇
妇产科学   1395篇
基础医学   9278篇
口腔科学   2556篇
临床医学   14991篇
内科学   17078篇
皮肤病学   1592篇
神经病学   5773篇
特种医学   5218篇
外国民族医学   1篇
外科学   13913篇
综合类   21748篇
现状与发展   13篇
一般理论   19篇
预防医学   13803篇
眼科学   1488篇
药学   11099篇
  116篇
中国医学   8456篇
肿瘤学   7280篇
  2024年   474篇
  2023年   1593篇
  2022年   3149篇
  2021年   4395篇
  2020年   3770篇
  2019年   2569篇
  2018年   3268篇
  2017年   3522篇
  2016年   3029篇
  2015年   4746篇
  2014年   6065篇
  2013年   7940篇
  2012年   10209篇
  2011年   10725篇
  2010年   8944篇
  2009年   8234篇
  2008年   8830篇
  2007年   8722篇
  2006年   7804篇
  2005年   6576篇
  2004年   5090篇
  2003年   4397篇
  2002年   3752篇
  2001年   2116篇
  2000年   1457篇
  1999年   925篇
  1998年   819篇
  1997年   746篇
  1996年   652篇
  1995年   566篇
  1994年   448篇
  1993年   446篇
  1992年   310篇
  1991年   287篇
  1990年   243篇
  1989年   262篇
  1988年   212篇
  1987年   197篇
  1986年   194篇
  1985年   202篇
  1984年   189篇
  1983年   184篇
  1982年   161篇
  1981年   163篇
  1980年   122篇
  1979年   84篇
  1978年   92篇
  1977年   78篇
  1976年   74篇
  1975年   57篇
排序方式: 共有10000条查询结果,搜索用时 281 毫秒
91.
肾移植术后并发尿路上皮肿瘤的临床分析   总被引:8,自引:0,他引:8  
目的 分析肾移植患者并发尿路上皮肿瘤的特点,探讨其诊治方法。方法 自1998~2003年肾移植患者1293例,术后发生尿路上皮恶性肿瘤21例(1.6%)。男4例,女17例。17例原发病为慢性问质性肾炎。发生尿路上皮肿瘤距肾移植6~62个月,平均26个月。其中膀胱癌6例,单侧肾盂或输尿管癌6例,单侧肾盂或输尿管、膀胱癌8例,双侧肾盂输尿管癌1例。10例上尿路肿瘤发生部位与移植肾同侧,4例发生于移植肾对侧。临床症状以无痛性肉服血尿和反复泌尿系感染为主。19例行手术治疗,术后所有患者免疫抑制剂用量减少1/3并辅以局部灌注化疗。结果 2例行姑息性治疗的晚期肿瘤患者分别于发现肿瘤5、8个月死亡。余19例现已随访2~5年。13例肿瘤复发,复发部位为膀胱或对侧原。肾、输尿管。所有患者在免疫抑制剂减量期间均未出现急性排斥。2例因切除移植肾恢复透析,17例肾功能正常。结论 慢性间质性。肾炎导致。肾功能衰竭的。肾移植患者和女性肾移植患者易发生移植后尿路上皮肿瘤;移植肾同侧上尿路较对侧好发肿瘤;对移植肾对侧为首发的上尿路发生肿瘤者可预防性行双侧上尿路根治性切除。  相似文献   
92.
93.
BACKGROUND: Until there is a definitive demonstration that early diagnosis and treatment of prostate cancer reduces disease-related mortality, it is imperative to promote informed screening decisions by providing balanced information about the potential benefits and risks of prostate cancer screening. Within a community/academic collaboration, we conducted a randomized trial of a printed booklet and a videotape that were designed for African American (AA) men. The purpose of the trial was to determine the effect of the interventions on knowledge, decisional conflict, satisfaction with the screening decision, and self-reported screening. METHODS: Participants were 238 AA men, ages 40 to 70 years, who were members of the Prince Hall Masons in Washington, DC. Men were randomly assigned to the (a) video-based information study arm, (b) print-based information study arm, or (c) wait list control study arm. Intervention materials were mailed to men at home. Assessments were conducted at baseline, 1 month, and 12 months postintervention. Multivariate analyses, including ANCOVA and logistic regression, were used to analyze group differences. RESULTS: The booklet and video resulted in a significant improvement in knowledge and a reduction in decisional conflict about prostate cancer screening, relative to the wait list control. Satisfaction with the screening decision was not affected by the interventions. Self-reported screening rates increased between the baseline and the 1-year assessment, although screening was not differentially associated with either of the interventions. In exploratory analyses, prostate-specific antigen testing at 1 year was more likely among previously screened men and was associated with having low baseline decisional conflict. CONCLUSIONS: This study represents one of the first randomized intervention trials specifically designed to address AA men's informed decision making about prostate cancer screening. We have developed and evaluated culturally sensitive, balanced, and disseminable materials that improved knowledge and reduced decisional conflict about prostate cancer screening among AA men. Due to the high incidence and mortality rates among AA men, there is a need for targeted educational materials, particularly materials that are balanced in terms of the benefits and risks of screening.  相似文献   
94.
曲美他嗪治疗冠心病心力衰竭的临床观察   总被引:16,自引:1,他引:15  
目的观察曲美他嗪治疗冠心病心力衰竭的临床疗效和安全性。方法选择冠心病心力衰竭患者86例,左心室射血分数(LVEF)均小于40%,NYHA心功能分级在Ⅲ~Ⅳ级。随机分成2组,对照组给予血管紧张素转换酶抑制剂(ACEI)或血管紧张素Ⅱ受体拮抗剂(ARB)、β-受体阻滞剂、利尿剂、醛固酮拮抗剂和洋地黄等基础药物治疗;治疗组在上述基础治疗上加用曲美他嗪20mg,3次/d治疗。观察时间为6个月。结果治疗组与对照组相比,3个月和6个月时LVEF、心功能分级及6min步行试验结果改善明显(P<0.05),且6个月较3个月时改善更明显,再住院次数亦明显减少,不良反应较少。结论曲美他嗪治疗冠心病心力衰竭的作用明显,是一种安全有效的新方法,其机制可能与改善缺血心肌的能量代谢有关。  相似文献   
95.
Much of the research on episodic memory in schizophrenia spectrum disorders has focused on memory deficits and how they relate to clinical measures such as outcome. Memory bias refers to the modulatory influence that state or trait psychopathology may exert on memory performance for specific categories of stimuli, often emotional in nature. For example, subjects suffering from depression frequently have better memory for negative stimuli than for neutral or positive ones. This dimension of memory function has received only scant attention in schizophrenia research but could provide fresh new insights into the relation between symptoms and neurocognition. This paper reviews the studies that have explored memory biases in individuals with schizophrenia. With respect to positive symptoms, we examine studies that have explored the link between persecutory delusions and memory bias for threatening information and between psychosis and a memory bias toward external source memory. Although relatively few studies have examined negative symptoms, we also review preliminary evidence indicating that flat affect and anhedonia may lead to some specific emotional memory biases. Finally, we present recent findings from our group delineating the relation between emotional valence for faces and memory bias toward novelty and familiarity, both in schizophrenia patients and in healthy control subjects. A better understanding of the biasing effects of psychopathology on memory in schizophrenia (but also on other cognitive functions, such as attention, attribution, and so forth) may provide a stronger association between positive and negative symptoms and memory function. Memory measures sensitive to such biases may turn out to be stronger predictors of clinical and functional outcome.  相似文献   
96.
97.
Intrastriatal transplantation of striatal neuroblasts from human fetuses is a promising approach for treatment of Huntington's disease, on the basis of many experimental animal studies and, most recently, pilot clinical trials. Technically, several issues remain to be resolved (e.g., the precise site of dissection of the fetal tissue; the number and location of the fetal striatal implants; or the use of immunosuppressive therapy), and await larger-scale trials and purposely designed protocols. Further clinical data must also be obtained, and preliminary promising results must be replicated in a patient group large enough to provide conclusive results. It is important to establish (1) the amount of clinical benefit provided to the patient by the grafted cells; (2) the anticipated duration of clinical benefits; and (3) the secondary rate of decline after the benefit of the graft has been overbalanced. Evaluation of these parameters will require very long-term follow-up of the patients involved, over several years after grafting, before the technique can eventually be proposed widely to patients.  相似文献   
98.
马庆久  石景森  要秀  邱随民  罗健 《医学争鸣》2002,23(21):1926-1928
目的 探讨耳穴脉冲电刺激治疗胆石症 ,胆绞痛的机制 .方法 选用 15条成年杂种犬 ,进行耳穴体表脉冲刺激与缩胆素 (CCK)对在体狗胆囊张力 ,Oddi括约肌张力及肌电活动影响的对比研究 .结果 耳穴脉冲电刺激对胆囊张力无明显影响 [(1.2 7± 0 .2 6 ) k Pa与 (1.2 4± 0 .2 2 ) k Pa,P<0 .0 5 ],CCK注射液能明显提高胆囊张力 [(1.2 7± 0 .2 6 ) k Pa与 (1.91± 0 .39) k Pa,P<0 .0 5 ],CCK注射液能明显降低Oddi括约肌张力 [(2 .2 4± 0 .5 5 ) k Pa与 (1.5 8± 0 .5 6 ) k Pa,P>0 .0 5 ]及肌电活动 .结论 耳穴脉冲电刺激同 CCK一样 ,均对 Oddi括约肌的张力有显著的降低作用 ,并减少 Oddi括约肌的肌电峰电位爆发波的频率与电压值 ,推测其对胆绞痛有治疗作用 ,并有助于胆结石的排石过程 .  相似文献   
99.
目的:制备高表达GM-CSF的淋巴瘤细胞系,观察淋巴瘤细胞转染GM-CSF基因后生物学特性的改变。方法:将小鼠GF-CSF真核表达质粒用电穿孔法导入小鼠淋巴瘤细胞系RMA,有限稀释法制备单个细胞克隆,经RT-PCR,骨髓祖细胞增殖实验和集落形成实验筛选相对高表达GM-CSF的RMA克隆,并观察其生物学特性的改变。结果:获得了高表达GM-CS的RMA细胞系,其同基因动物体内致瘤性降低。结论:淋巴瘤细胞系RMA转染GM-CSF基因后致瘤性降低。  相似文献   
100.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号